

Vicore further strengthens patent protection for C21

Stockholm, June 7, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”) today announces that the European Patent Office (EPO) has granted Vicore’s patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF).

The European patent protection:

- relates to any form of enteric coating of C21, and
- is not limited to any specific disease

The EPO today granted European Patent No. EP 4 138 789 B1 entitled **“New Delayed Release Composition for Peroral Administration”**, relating to a new invention that fundamentally improves the oral uptake of C21. The patent protects any form of enteric coating of C21 in Europe and is expected to last at least until 2041. The equivalent US patent was recently granted by the United States Patent and Trademark Office (USPTO), and corresponding patent applications have been filed in multiple other jurisdictions, including China and Japan.

Carl-Johan Dalsgaard, CEO of Vicore comments *“We are very pleased that this patent, providing strong protection for C21 in all diseases, has now been granted in both Europe and in the US”. “The European IPF market alone represents a large opportunity with 100,000 diagnosed patients. The combined US and European IPF market represent \$3bn in annual sales. This patent also allows us to explore wider pulmonary fibrosis indications outside IPF as well as pulmonary hypertension.”*

In an interim analysis of the ongoing phase 2a trial, presented at ATS 2023 and in a subsequent [webcast](#), C21 has shown unmatched effects by increasing lung capacity in patients with IPF, a devastating disease which, if untreated, can result in a steady decline in lung capacity and a typical life expectancy of three to five years after diagnosis. C21, an angiotensin II type 2 receptor agonist (ATRA), acts by preventing the scarring process characteristic of IPF, thereby restoring alveolar integrity and improving lung function.

For further information, please contact:

Vicore Pharma

Carl-Johan Dalsgaard, CEO

Phone: +46 70 975 98 63

E-mail: carl-johan.dalsgaard@vicorepharma.com

Optimum Strategic Communications

Hana Malik, Eleanor Cooper, Katie Flint

Phone: +44 20 3882 2119

E-mail: vicore@optimumcomms.com

This information was submitted for publication on June 7 at 08:00 CET.

About the renin-angiotensin system (RAS) and angiotensin II type 2 receptor (AT2 receptor)

RAS is a hormone system that regulates several important physiological processes. In this system, the AT1 receptor is a well-established drug target with angiotensin receptor blockers (ARBs) as a drug class, while the AT2 receptor has been more elusive and difficult to study. The AT2 receptor is part of the body's resolution and repair system and is thought to be protective in several diseases connected to ageing and cell senescence, including idiopathic pulmonary fibrosis (IPF), chronic kidney disease and heart failure, as well as cognitive disorders. Stimulating the AT2 receptor has been shown to be effective in combating disease in numerous animal models and clinical validation is well advanced in lung disease. Stimulating the AT2 receptor also dilates small diseased resistance vessels in animals and in humans, resulting in locally increased blood flow. With C21 as the first-in-class highly selective small molecule AT2 receptor agonist (ATRAG) taken into clinical trials, the therapeutic benefit of targeting the AT2 receptor is becoming increasingly apparent. Vicore is developing C21 for rare lung diseases and has a series of new ATRAGs in development for other indications, the first of which (C106) is in clinical phase 1.

About Vicore Pharma Holding AB (publ)

Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in a phase 2a study of IPF. C21 is protected by US and European Orphan Designation. A variety of patents have been filed to provide further protection for C21, out to 2040 and onwards. Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. Using its unique expertise in the ATRAG biology Vicore is further fueling its pipeline with several new small molecule drug assets, with long patent life and for a variety of indications, some of which could be partnered while others may be taken to the market by Vicore.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com

Attachments

[Vicore further strengthens patent protection for C21](#)